Cxcr2 - C-X-C motif chemokine receptor 2 Gene

Rattus norvegicus

Also known as Il8rb; Cmkar2

Gene ID: 29385 | Gene type: protein coding

About Cxcr2

Primary_assembly 9: 75,729,115-75,739,425 forward strand.mRatBN7.2:CM026982.1

This gene has 1 transcript (splice variant), 244 orthologues, 24 paralogues and is associated with 45 phenotypes. Biased expression in Spleen (RPKM 23.5), Lung (RPKM 14.1) and 4 other tissues.

Summary

Predicted to enable chemokine binding activity and Chemokine Receptor activity. Involved in several processes, including neutrophil chemotaxis; positive regulation of neutrophil chemotaxis; and regulation of apoptotic process. Predicted to be located in several cellular components, including cell surface; mast cell granule; and mitotic spindle. Predicted to be active in external side of plasma membrane. Used to study colitis; demyelinating disease; and nephritis. Biomarker of periapical periodontitis. Human ortholog(s) of this gene implicated in IgA glomerulonephritis; acute pyelonephritis; end stage renal disease; and urinary bladder Cancer. Orthologous to human CXCR2 (C-X-C motif Chemokine Receptor 2). [provided by Alliance of Genome Resources, Apr 2022]

Cxcr2 Products(1)

mRNA	Protein	Name
NM_017183.2	NP_058879.1	C-X-C chemokine receptor type 2

Cxcr2 Protein Structure

7tmA_CXCR1_2

0
100
200
300
359 a.a.

Protein Preferred Names

Protein Names

C-X-C chemokine receptor type 2

CXC-R2	CXCR-2
GRO/MGSA receptor	IL-8R B
chemokine (C-X-C motif) receptor 2	chemokine (C-X-C) receptor 2
high affinity interleukin-8 receptor B	interleukin 8 receptor, beta

Related Agents

Clinical Phase

Bioactive Molecules (9)

Cat. No.	Product Name	Effect	Purity	Phase
HY-15251	Reparixin	Inhibitor	99.95%	Phase 3
HY-15252	Reparixin L-lysine salt	Inhibitor	99.66%	Phase 3
HY-19519A	Ladarixin sodium	Antagonist	99.15%	Phase 3
HY-10198	Navarixin	Antagonist	98.90%	Phase 2
HY-13848	AZD8797		98.73%	Phase 2
HY-19855	AZD-5069	Antagonist	99.76%	Phase 2
HY-119339	SX-682	Inhibitor	99.67%	Phase 2
HY-19768	Danirixin	Antagonist	98.45%	Phase 2
HY-18263C	Elubrixin tosylate	Antagonist	99.78%	Phase 2

Pre-clinical Phase

Bioactive Molecules (18)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-16711	SB225002	Antagonist	99.87%	Unkown
HY-50688	SB-265610	Antagonist	≥99.0%	Unkown
HY-101407	Nicotinamide N-oxide	Antagonist	99.85%	Unkown
HY-101022	CXCR2-IN-1	Inhibitor	99.47%	Unkown
HY-147392	CXCR2 antagonist 8	Antagonist	99.24%	Unkown
HY-120878	CXCR2-IN-2	Antagonist	99.52%	Unkown
HY-13021	SRT3190	Antagonist	99.77%	Unkown
HY-119259	AZD8309	Antagonist	99.98%	Unkown
HY-10011	SCH 563705	Antagonist	98.20%	Unkown
HY-15462	SRT3109	Antagonist	99.82%	Unkown
HY-P4846	Ac-Pro-Gly-Pro-OH	Agonist	/	Unkown
HY-144784	CXCR2 antagonist 7	Antagonist	/	Unkown
HY-101407R	Nicotinamide N-oxide (Standard)	Antagonist	/	Unkown
HY-124056	AZ10397767	Antagonist	/	Unkown
HY-N2573	Corydalmine	Inhibitor	/	Unkown
HY-144781	CXCR2 antagonist 5	Antagonist	/	Unkown
HY-144780	CXCR2 antagonist 4	Antagonist	/	Unkown
HY-144783	CXCR2 antagonist 6	Antagonist	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Cxcr2	NCBI	NCBI:3579
Mus musculus	Cxcr2	NCBI	NCBI:12765

Name
Email *

	Sorry, but the email address you supplied was invalid.